方盛制药：紫英颗粒获得《药物临床试验批准通知书》

Group 1 - The core point of the article is that Hunan Fangsheng Pharmaceutical Co., Ltd. announced that its subsidiary, Guangdong Fangsheng R&D Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of its innovative traditional Chinese medicine project, Ziying Granules [2] Group 2 - The approval signifies a significant step in the development of innovative drugs within the traditional Chinese medicine sector [2] - This development may enhance the company's portfolio and potentially lead to new revenue streams in the pharmaceutical market [2] - The clinical trial approval reflects the growing recognition and regulatory support for traditional Chinese medicine in the broader pharmaceutical industry [2]